FDA approvals: Trutakna leads 8 actions

From July 3 at 5:35 p.m. through July 10 at 5:00 p.m. UTC-05:00, the tracked FDA approval window produced eight new actions: one novel drug approval, two drug label or formulation expansions, one device PMA approval, and four device 510(k) clearances. 1 2 3 4 5 6 7 8 The device count carries a coverage caveat: the five device actions below are confirmed through company and trade disclosures, but they should not be read as a complete FDA 510(k) database reconciliation for late-posted or undisclosed filings.

Trutakna is the week's lead approval because it creates a new immunology category inside IgA nephropathy, a kidney disease in which abnormal IgA immune complexes can drive progressive renal injury. FDA approved Vera Therapeutics' atacicept-vymj as the first FDA-approved medicine targeting both B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), two immune signals involved in B-cell and plasma-cell activity. 1 FDA granted the therapy priority review and breakthrough therapy designation, and the agency emphasized that lower proteinuria has not yet been proven to slow long-term renal-function decline for Trutakna patients. 1

The label is narrow but commercially meaningful. The approved regimen is 150 mg by subcutaneous injection once weekly through a prefilled autoinjector, and FDA states that ORIGIN 3 must verify whether Trutakna reduces loss of kidney function over time. 1 Vera said the ongoing ORIGIN 3 trial's eGFR data were expected in the third quarter of 2026, making that readout the next clinical catalyst for the accelerated-approval file. 11

The pivotal efficacy readout is strong on the surrogate endpoint. In the prespecified 36-week interim analysis of ORIGIN 3, Trutakna reduced 24-hour urine protein-to-creatinine ratio by 46% from baseline and by 42% versus placebo in 203 patients, with p<0.0001. 1 Vera reported that Gd-IgA1, an IgAN biomarker, fell 68% in an observational secondary endpoint that was not adjusted for multiplicity. 11 The common adverse-reaction pattern also matters for adoption: Vera reported infection in 32% of Trutakna patients versus 28% for placebo and injection-site reactions in 30% versus 5%. 11

For investors, the first decision point is launch execution against an increasingly crowded IgAN market. BioPharma Dive reported Trutakna's annual list price at $425,000, above Otsuka's Voyxact at $390,000, and cited Vera's argument that Trutakna has the strongest dataset so far. 12 The same category is moving fast: MedCity News reported Vertex's povetacicept, another dual BAFF/APRIL inhibitor, has a November 30, 2026 PDUFA date after Vertex's $4.9 billion Alpine Immune Sciences acquisition. 13 Clinicians and advocates should treat the launch as a proteinuria-reduction option with a confirmatory-evidence obligation, not as a settled renal-outcomes drug.

Keytruda and Padcev had the largest immediate practice-change signal. FDA approved pembrolizumab, either as intravenous Keytruda or subcutaneous Keytruda Qlex, with enfortumab vedotin-ejfv for neoadjuvant and adjuvant treatment of all cystectomy-eligible adults with MIBC. 2 The prior US perioperative label from 2025 was limited to cisplatin-ineligible patients, so the July 10 expansion moves the regimen into cisplatin-eligible patients as well. 14

The KEYNOTE-B15/EV-304 data explain why this label matters. In 808 patients, pembrolizumab plus enfortumab vedotin reduced event-free survival risk versus gemcitabine plus cisplatin, with an EFS hazard ratio of 0.53, a 95% confidence interval of 0.41 to 0.70, and p<0.0001; median EFS was not reached in the combination arm versus 48.5 months for chemotherapy. 2 Overall survival also favored the combination, with an OS hazard ratio of 0.65, a 95% confidence interval of 0.48 to 0.89, and p=0.0029. 2 The pathologic complete response rate was 55.8% for pembrolizumab plus enfortumab vedotin versus 32.5% for chemotherapy. 2

Clinicians should read this as a perioperative pathway update, not only a drug-pair update. Merck said Keytruda Qlex, the subcutaneous pembrolizumab formulation with berahyaluronidase alfa-pmph, can be injected in about one to two minutes and now carries the MIBC label alongside intravenous pembrolizumab. 14 Pfizer and Astellas said the regimen was approved before the August 17 PDUFA date and reviewed through Project Orbis with regulators in Australia, Canada, Switzerland, the United Kingdom, and Israel. 15 For investors, the cleaner question is whether perioperative use expands duration and patient reach without cannibalizing later-line Padcev-Keytruda use.

Sarclisa Escena is a different kind of oncology approval: the molecule is familiar, but the delivery model changed. FDA approved isatuximab-irfc for subcutaneous injection across multiple myeloma indications already covered by intravenous Sarclisa, and Sanofi said it is the first US anticancer treatment administered through an on-body injector. 3 10

The evidence base supports convenience without giving up response. In the 531-patient IRAKLIA Phase 3 trial, Sarclisa Escena plus pomalidomide and dexamethasone produced an overall response rate of 71.1% versus 70.5% for intravenous isatuximab plus the same backbone, meeting noninferiority with a response-rate ratio of 1.008 and a 95% confidence interval of 0.903 to 1.126. 3 FDA reported systemic administration reactions in 1.5% of the subcutaneous arm versus 25% of the intravenous arm, while injection-site reactions occurred in 0.4% of 5,145 injections. 3

The commercial fight is against Johnson & Johnson's Darzalex Faspro, the earlier subcutaneous anti-CD38 standard in multiple myeloma. Pharmacy Times reported Sarclisa Escena is hyaluronidase-free, uses a 10 mL injection, and can be delivered with a 30-gauge needle through a hands-free, battery-free CirCLIQ on-body injector using about 7 psi of pressure. 16 Sanofi said more than 70,000 patients globally have received Sarclisa and that the product is approved in nearly 60 countries across four indications. 10 Oncology infusion centers should update formularies and chair-time assumptions; investors should watch how quickly Sanofi converts IV Sarclisa accounts to the on-body option.

Johnson & Johnson's Dual Energy THERMOCOOL SMARTTOUCH SF Platform is the only PMA device approval in this window. The device integrates radiofrequency and pulsed field energy delivery through one catheter and connects with CARTO 3D mapping, PF Index guidance, and contact-force monitoring for atrial fibrillation ablation. 4 J&J said the first US procedures are expected in summer 2026 through a phased commercial rollout. 4 MedTech Dive reported that Boston Scientific and Medtronic reached the pulsed-field ablation market before J&J, and RBC channel checks suggested dual-energy catheters were used in 20% to 30% of European cases. 17 The investor read is market-share recovery in complex electrophysiology procedures.

Philips' Alturion ultrasound launch is a throughput story. Philips said Alturion is designed for high-volume clinical environments and includes AI-powered Elevate Plus measurements for abdominal ultrasound, a 24-inch monitor, a smaller footprint, interchangeable transducers compatible with EPIQ Elite and Affiniti, and Collaboration Live tele-ultrasound support. 8 The buyer decision is less about a new clinical indication and more about whether shared probes, remote support, and automated measurements reduce exam variability in busy departments.

The orthopedic clearances have narrower but concrete workflow hooks. Movmedix's LARS ACJ system is a third-generation polyethylene terephthalate synthetic ligament scaffold for ACJ separations, and Movmedix said the broader LARS platform has been used in more than 250,000 patients across more than 11 clinical indications. 5 AlloSource's RECONNEX Pre-Sutured Tendon is a ready-to-use allograft measured under tension in 8 mm to 10.5 mm diameters, and AlloSource said the product is processed with its AlloTrue Cleansing Process plus low-dose, low-temperature electron-beam sterilization. 6 For sports-medicine teams, both actions point to setup time, graft consistency, and surgeon education rather than a broad new disease market.

Zeta Surgical's clearance brings robotic positioning into transcranial magnetic stimulation, a neuromodulation procedure used mainly for treatment-resistant depression. 7 Zeta said the system is classified as a Class II stereotaxic instrument under 21 CFR 882.4560, carries 510(k) number K261471, provides submillimeter-level robotic coil positioning, tracks patient movement in real time, and can be set up in under one minute. 7 Mental-health clinics should watch whether the system reduces operator variability enough to justify capital or service-model changes.

Investors have three follow-up variables. Vera's Trutakna launch depends on payer coverage, specialty-pharmacy execution, and the ORIGIN 3 renal-function readout expected in the third quarter of 2026. 11 Merck, Pfizer, and Astellas need perioperative MIBC uptake to show that earlier-line Padcev-Keytruda use expands the franchise rather than only shifting revenue timing. 14 Sanofi's Sarclisa Escena launch depends on whether the on-body injector gives clinics enough workflow advantage to compete more directly with Darzalex Faspro. 16

Clinicians should update three protocols first: IgAN treatment sequencing with an accelerated-approval BAFF/APRIL option, MIBC perioperative pathway planning across cisplatin eligibility, and multiple myeloma administration workflows for subcutaneous isatuximab. 1 2 3 Patient advocates should focus on access language: Trutakna's confirmatory-trial requirement, Padcev-Keytruda's expanded perioperative eligibility, and Sarclisa Escena's potential to reduce infusion burden are the clearest practical changes from this window. 1 2 10